Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.03 (market cap $1.74B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.63 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| NUVB | SLS | |
|---|---|---|
Market Cap | $1.74B | $2.27B |
Volume | 9,289,619 | 4,179,659 |
Sector | Health | Health |
52-Week High | $9.54 | $15.46 |
52-Week Low | $3.41 | $1.39 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $1.33B | $2.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
